GSTM1缺失与肾衰竭及心力衰竭相关
在ARIC社区前瞻性队列中,白人和黑人参与者GSTM1零拷贝或一拷贝比例较高;中位随访24.6年,校正人口学、糖尿病和高血压后,零或一拷贝GSTM1与肾衰竭和心力衰竭风险升高相关,零拷贝与一拷贝间风险无显著差异。
要点
- GSTM1零或一拷贝与肾衰竭风险升高相关(aHR 1.66,95%CI 1.27-2.17)。
- GSTM1零或一拷贝与心力衰竭风险升高相关(aHR 1.16,95%CI 1.04-1.29)。
- 零拷贝与一拷贝GSTM1间风险无显著差异(P>0.10)。
核心结论
- GSTM1缺失与 incident 肾衰竭和心力衰竭显著相关,独立于传统危险因素。
- GSTM1功能可能是预防肾衰竭和心力衰竭的潜在治疗靶点。
研究设计与样本
- 基于ARIC社区前瞻性队列,使用外显子测序reads估计GSTM1拷贝数,纳入白人和黑人参与者。
- 肾衰竭分析纳入5715例无 prevalent 肾衰竭参与者,心力衰竭分析纳入5368例无 prevalent 心力衰竭参与者。
主要发现
- 白人参与者中GSTM1零拷贝和 one 拷贝比例分别为51.2%和39.8%,黑人参与者分别为25.6%和48.5%。
- 中位随访24.6年,发生256例肾衰竭事件和1028例心力衰竭事件。
- 校正人口学、糖尿病和高血压后,零或一拷贝GSTM1与肾衰竭风险升高相关(aHR 1.66,95%CI 1.27-2.17)。
- 校正后零或一拷贝GSTM1与心力衰竭风险升高相关(aHR 1.16,95%CI 1.04-1.29)。
- 零拷贝与一拷贝GSTM1间风险无显著差异(P>0.10)。
临床怎么用
- GSTM1拷贝数缺失可能作为肾衰竭和心力衰竭风险分层参考,但需进一步验证。
- GSTM1功能作为治疗靶点尚处探索阶段,暂不改变临床实践。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Glutathione S-transferase mu 1 (GSTM1) encodes an enzyme that catalyzes the conjugation of electrophilic compounds with glutathione to facilitate their degradation or excretion. The loss of one or both copies of GSTM1 is common in many populations and has been associated with CKD progression. With the hypothesis that the loss of GSTM1 is also associated with incident kidney failure and heart failure, we estimated GSTM1 copy number using exome sequencing reads in the Atherosclerosis Risk in Communities (ARIC) Study, a community-based prospective cohort of white and black participants. Overall, 51.2% and 39.8% of white participants and 25.6% and 48.5% of black participants had zero or one copy of GSTM1, respectively. Over a median follow-up of 24.6 years, 256 kidney failure events occurred in 5715 participants without prevalent kidney failure, and 1028 heart failure events occurred in 5368 participants without prevalent heart failure. In analysis adjusted for demographics, diabetes, and hypertension, having zero or one copy of GSTM1 associated with higher risk of kidney failure and heart failure (adjusted hazard ratio [95% confidence interval] for zero or one versus two copies of GSTM1: kidney failure, 1.66 [1.27 to 2.17]; heart failure, 1.16 [1.04 to 1.29]). Risk did not differ significantly between participants with zero and one copy of GSTM1 (P>0.10). In summary, the loss of GSTM1 was significantly associated with incident kidney and heart failure, independent of traditional risk factors. These results suggest GSTM1 function is a potential treatment target for the prevention of kidney and heart failure.
引用
- Tin A, Scharpf R, Estrella MM, et al. The Loss of GSTM1 Associates with Kidney Failure and Heart Failure. J Am Soc Nephrol. 2017. PMID: 28720685. doi:10.1681/ASN.2017030228
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。